XERS · CIK 0001867096 · operating
Xeris Biopharma Holdings is a commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological disorders. The company's marketed products include Gvoke, a ready-to-use liquid-stable glucagon formulation for severe hypoglycemia treatment in pediatric and adult patients; Keveyis, indicated for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia in adult patients with Cushing's syndrome. The company is also developing XP-8121, a once-weekly subcutaneous levothyroxine injection currently in phase 3 clinical trials for hypothyroidism treatment.
Xeris operates with approximately 394 full-time employees and is headquartered in Chicago, Illinois. The company was incorporated in 2005 and is traded on the Nasdaq under the ticker XERS, with a market capitalization of approximately $1.0 billion. The company's revenue is generated primarily through product sales of its marketed therapeutics in the endocrine disease space.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.37 | $-0.37 | +17.8% | |
| 2023 | $-0.45 | $-0.45 | +35.7% | |
| 2022 | $-0.70 | $-0.70 | — | |
| 2021 | — | — | — |